CN114903990A - 用于逆转突触和树突棘损失的多种趋化因子受体的口服肽拮抗剂 - Google Patents

用于逆转突触和树突棘损失的多种趋化因子受体的口服肽拮抗剂 Download PDF

Info

Publication number
CN114903990A
CN114903990A CN202110921599.2A CN202110921599A CN114903990A CN 114903990 A CN114903990 A CN 114903990A CN 202110921599 A CN202110921599 A CN 202110921599A CN 114903990 A CN114903990 A CN 114903990A
Authority
CN
China
Prior art keywords
thr
loss
ser
peptide
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110921599.2A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·R·鲁夫
吉拉·罗斯纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovative Biopeptide Co ltd
Original Assignee
Innovative Biopeptide Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Biopeptide Co ltd filed Critical Innovative Biopeptide Co ltd
Publication of CN114903990A publication Critical patent/CN114903990A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202110921599.2A 2020-02-06 2021-08-11 用于逆转突触和树突棘损失的多种趋化因子受体的口服肽拮抗剂 Pending CN114903990A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970869P 2020-02-06 2020-02-06
US17/170,790 US20210244788A1 (en) 2020-02-06 2021-02-08 Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines
US17/170,790 2021-02-08

Publications (1)

Publication Number Publication Date
CN114903990A true CN114903990A (zh) 2022-08-16

Family

ID=77178645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110921599.2A Pending CN114903990A (zh) 2020-02-06 2021-08-11 用于逆转突触和树突棘损失的多种趋化因子受体的口服肽拮抗剂

Country Status (3)

Country Link
US (2) US20210244788A1 (https=)
JP (1) JP2022121359A (https=)
CN (1) CN114903990A (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025124536A1 (zh) * 2023-12-15 2025-06-19 江苏康缘药业股份有限公司 趋化因子受体8拮抗多肽化合物、组合物、试剂盒及用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116990520A (zh) * 2022-04-25 2023-11-03 中国科学院深圳先进技术研究院 一种蛋白棒状体标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322252A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
US20190022166A1 (en) * 2017-07-18 2019-01-24 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567682A (en) * 1988-12-16 1996-10-22 Advanced Peptides And Biotechnology Sciences Method of treating Alzheimer's disease
AU2006261133B2 (en) * 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines
WO2019135995A1 (en) * 2018-01-02 2019-07-11 Rush University Medical Center Compositions and methods for treating neurological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322252A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
US20190022166A1 (en) * 2017-07-18 2019-01-24 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONAGHY P C等: "The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis", ALZHEIMER\'S RESEARCH & THERAPY, vol. 6, no. 4, 21 July 2014 (2014-07-21), pages 46 *
OLIVEIRA DA SILVA等: "Cofilin pathology is a new player on α-synuclein-induced spine impairment in models of hippocampal synucleinopathy", BIORXIV, 2 February 2021 (2021-02-02), pages 1 - 24 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025124536A1 (zh) * 2023-12-15 2025-06-19 江苏康缘药业股份有限公司 趋化因子受体8拮抗多肽化合物、组合物、试剂盒及用途

Also Published As

Publication number Publication date
US20210244788A1 (en) 2021-08-12
US20240238363A1 (en) 2024-07-18
JP2022121359A (ja) 2022-08-19

Similar Documents

Publication Publication Date Title
US6818407B2 (en) Anti-endotoxic antimicrobial cationic peptides and methods of use therfor
DE60031792T2 (de) Schimärische amyloid-beta peptide
US20240238363A1 (en) Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines
US10501494B2 (en) Uses of peptides to treat brain injury and disease
CN101361961B (zh) 多肽小分子在制备防治缺血性脑血管病药物中的应用
DE69626034T2 (de) Zusammensetzung für verbesserung der pankreasfunktion
Lübke et al. Neurotrophic factors in Alzheimer’s disease: Pathogenesis and therapy
Uzakov et al. Lentiviral-mediated overexpression of nerve growth factor (NGF) prevents beta-amyloid [25–35]-induced long term potentiation (LTP) decline in the rat hippocampus
US9149509B2 (en) Methods for improving neurological outcome after neural injury and neurodegenerative disease
JP5219168B2 (ja) アルツハイマー病の予防および／または治療用βシート破壊ペプチド
EP2991664B1 (de) Agenzien zur prävention und therapie von folgeerkrankungen von hiv und anderer viraler infektionen
CN115475247B (zh) β2-微球蛋白或其抑制剂的制药用途
HK40079377A (en) Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines
DE69932834T2 (de) Neue Peptide
DE602004001509T2 (de) Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
CN118620031B (zh) 以PresoCT结构域为作用靶点的多肽及其在制备神经保护药物中的用途
EP4039264A1 (en) Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines
DE112015000456T5 (de) Verfahren und Zusammensetzungen zur Verwendung in der Behandlung inflammatorischer und Autoimmun-Krankheiten
DE4413938A1 (de) Peptide als Therapeutikum für Autoimmunerkrankungen
CN107779437B (zh) 自噬诱导剂作为微管稳定药物促进神经再生的用途
DE60036638T2 (de) Verwendung von colostrinin, dessen peptidbestandteile und deren analoga zur förderung der neuronalen zelldifferenzierung
US20180066027A1 (en) Protamine in treatment of neuronal injuries
Liu et al. Regulation of axonal regeneration following the central nervous system injury in adult mammalian
WO2011021832A2 (ko) 척수 손상 예방 또는 치료용 조성물
EP1471943A2 (de) Konjugat zur behandlung prokaryontischer infektionen

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079377

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination